Abstract
Early diagnosis of melanoma is crucial to improved patient prognosis but can be difficult to achieve from histopathology alone. PRAME is used increasingly in dermatology as an ancillary tool to help differentiate between benign vs. malignant melanocytic tumors. S100A8 is another biomarker found to be expressed in melanoma-associated epidermal keratinocytes, but its diagnostic utility has not been compared to other biomarkers, including PRAME. In this retrospective case-control study, we compared S100A8 and PRAME immunohistochemistry (IHC) in melanocytic nevi and melanoma (n=209).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
